Good morning :)
Place Order
Add to Watchlist

Procter & Gamble Health Ltd

PGHL Share Price

5,677.500.27% (-15.50)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹9,424 cr, stock is ranked 575

Stock is 1.89x as volatile as Nifty

PGHL Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹9,424 cr, stock is ranked 575

Stock is 1.89x as volatile as Nifty

PGHL Performance & Key Metrics

PGHL Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
37.5217.514.58%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.596.400.79%

PGHL Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

PGHL Company Profile

Procter & Gamble Health Limited, formerly Merck Limited, is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments

Investor Presentation

View older View older 

Jun 16, 2025

PDF
View Older Presentations

PGHL Similar Stocks (Peers)

Compare with peers Compare with peers 

PGHL Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.50
36.50
1Y Return
4.00%
4.00%
Buy Reco %
87.10
87.10
PE Ratio
22.64
22.64
1Y Return
2.34%
2.34%
Buy Reco %
73.33
73.33
PE Ratio
59.13
59.13
1Y Return
13.13%
13.13%
Buy Reco %
70.83
70.83
PE Ratio
18.58
18.58
1Y Return
4.24%
4.24%
Buy Reco %
51.72
51.72
PE Ratio
52.73
52.73
1Y Return
18.31%
18.31%
Buy Reco %
81.25
81.25
Compare with Peers

PGHL Sentiment Analysis

PGHL Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

PGHL Stock Summary · June 2025

The company demonstrated robust fiscal performance for the nine-month period ending March 31, 2025, with an 8% sales increase and a remarkable 27% rise in profit after tax, underscoring the effectiveness of its integrated growth strategy. Despite navigating a challenging macroeconomic landscape, management remains committed to enhancing product superiority and expanding market share, particularly through innovative e-commerce initiatives and a new distribution model aimed at rural outreach. The emphasis on consumer health, particularly addressing Vitamin B deficiency, has fostered positive market sentiment, bolstered by educational campaigns that raise awareness of product benefits. Continuous engagement with healthcare professionals and consumer feedback integration are pivotal in driving innovation and maintaining brand loyalty, positioning the company for sustained growth and operational excellence.

PGHL Stock Growth Drivers
PGHL Stock Growth Drivers
6
  • Strong Financial Performance

    The company has reported significant financial achievements, including an 8% increase in sales to Rs.

  • Effective Integrated Growth Strategy

    The company's Integrated Growth Strategy has been pivotal in driving growth and profitability. It focuses

PGHL Stock Challenges
PGHL Stock Challenges
0
No ConsHmm, looks like there are no
challenges

PGHL Forecast

PGHL Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

PGHL

PGHL

Income

Balance Sheet

Cash Flow

PGHL Income Statement

PGHL Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,424.751,026.831,127.601,248.011,166.891,230.53
Raw Materialssubtract444.47310.39344.55358.99329.69871.60
Power & Fuel Costsubtract19.0912.9714.7012.888.50
Employee Costsubtract182.93153.66167.56206.17215.16
Selling & Administrative Expensessubtract257.28173.99203.91196.86181.66
Operating & Other expensessubtract136.68111.70116.01130.04130.44
Depreciation/Amortizationsubtract29.4530.0427.0828.1027.4023.85
Interest & Other Itemssubtract0.000.800.420.770.720.63
Taxes & Other Itemssubtract100.7756.4860.8584.7372.3483.26
EPS153.07106.51115.98138.24121.08151.32
DPS230.00130.0052.5095.00260.00140.00
Payout ratio1.501.220.450.692.150.93

PGHL Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

Jun 16PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual Report Unavailable

FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

PGHL Stock Peers

PGHL Past Performance & Peer Comparison

PGHL Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Procter & Gamble Health Ltd46.8917.514.58%
Sun Pharmaceutical Industries Ltd36.505.500.96%
Cipla Ltd22.643.821.08%
Torrent Pharmaceuticals Ltd59.1314.890.18%

PGHL Stock Price Comparison

Compare PGHL with any stock or ETF
Compare PGHL with any stock or ETF
PGHL
Loading...

PGHL Holdings

PGHL Shareholdings

PGHL Promoter Holdings Trend

PGHL Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

PGHL Institutional Holdings Trend

PGHL Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

PGHL Shareholding Pattern

PGHL Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding51.82%10.54%3.67%6.87%27.11%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

PGHL Shareholding History

PGHL Shareholding History

Dec '23MarJunSepDec '24Mar7.59%6.24%6.40%6.61%7.02%6.87%

Mutual Funds Invested in PGHL

Mutual Funds Invested in PGHL

No mutual funds holding trends are available

Top 5 Mutual Funds holding Procter & Gamble Health Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
4.3102%0.61%-0.02%118/248 (-8)
2.1945%2.42%-0.11%7/132 (-4)
1.4990%4.94%0.24%3/56 (+1)

Compare 3-month MF holding change on Screener

PGHL Insider Trades & Bulk Stock Deals

PGHL Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing PGHL stock

smallcases containing PGHL stock

Looks like this stock is not in any smallcase yet.

PGHL Events

PGHL Events

PGHL Dividend Trend

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 4.58%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹45.79 every year

Dividends

Corp. Actions

Announcements

Legal Orders

PGHL Dividend Trend

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 4.58%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹45.79 every year

PGHL Upcoming Dividends

PGHL Upcoming Dividends

No upcoming dividends are available

PGHL Past Dividends

PGHL Past Dividends

Cash Dividend

Ex DateEx DateFeb 21, 2025

Interim
Interim | Div/Share: ₹80.00

Dividend/Share

80.00

Ex DateEx Date

Feb 21, 2025

Cash Dividend

Ex DateEx DateNov 28, 2024

Final
Final | Div/Share: ₹60.00

Dividend/Share

60.00

Ex DateEx Date

Nov 28, 2024

Cash Dividend

Ex DateEx DateFeb 14, 2024

Interim
Interim | Div/Share: ₹50.00

Dividend/Share

50.00

Ex DateEx Date

Feb 14, 2024

Cash Dividend

Ex DateEx DateFeb 14, 2024

Special
Special | Div/Share: ₹150.00

Dividend/Share

150.00

Ex DateEx Date

Feb 14, 2024

Cash Dividend

Ex DateEx DateNov 23, 2023

Final
Final | Div/Share: ₹50.00

Dividend/Share

50.00

Ex DateEx Date

Nov 23, 2023

PGHL Stock News & Opinions

PGHL Stock News & Opinions

Corporate
Procter & Gamble Health to conduct board meeting

Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Board of Procter & Gamble Health recommends final dividend

Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 45 per equity Share (i.e. 450%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 31.40% in the March 2025 quarter

Net profit of Procter & Gamble Health rose 31.40% to Rs 61.18 crore in the quarter ended March 2025 as against Rs 46.56 crore during the previous quarter ended March 2024. Sales rose 23.17% to Rs 310.99 crore in the quarter ended March 2025 as against Rs 252.48 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales310.99252.48 23 OPM %26.0226.71 - PBDT83.9069.56 21 PBT78.5362.72 25 NP61.1846.56 31 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Procter & Gamble Health declare Quarterly Result

Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter

Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales309.77309.97 0 OPM %39.8532.79 - PBDT127.24106.64 19 PBT121.6999.72 22 NP90.9072.07 26 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Board of Procter & Gamble Health recommends interim dividend

Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share

The company's revenue from operations remained flat to Rs 309.77 crore in Q3 FY25, compared to the same quarter of the previous year. Total expenses were at Rs 192.04 crore in Q2 December 2024, down 10.85% on a YoY basis. The cost of materials consumed stood at Rs 61.60 crore (down 10.85% YoY), while employee benefits expenses came in at Rs 61.60 crore (down 13.04% YoY) during the period under review. Milind Thatte, Managing Director, P&G Health India, said, 'This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.' Meanwhile, the board has declared an interim dividend of Rs 80 per equity share for the financial year 2024-25. The record date for the dividend will be 21 February 2025. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Procter & Gamble Health announces board meeting date

Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

6 months agoCapital Market - Live
Spotlight
P&G Health hits 52 week high as Q2 PAT jumps 26% YoY to Rs 82 cr

Profit before tax in Q2 FY25 stood at Rs 111.4 crore, up 26.51% as against Rs 88.05 crore posted in same quarter last year. Total expenses were at Rs 205.29 crore in Q2 September 2024, down 7.91% on YoY basis. Cost of materials consumed stood at Rs 48.17 crore (down 44.82% YoY) while employee benefits expenses came in at Rs 46.22 crore (down 23.77% YoY) during the period under review. Milind Thatte, Managing Director, P superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organization'. He further added, 'We are dedicated to enhancing consumer awareness programs and strengthening our relationships with our customers and stakeholders. We continue to invest in initiatives that address the evolving needs of both consumers and healthcare professionals, along with strengthening our go-to-market model. We have also strengthened our reach, distribution, and retail execution, positioning us for long-term competitiveness'. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The counter has hit a 52-week high at Rs 5,730.75 in today's intra-day session.Powered by Capital Market - Live

8 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 25.56% in the September 2024 quarter

Net profit of Procter & Gamble Health rose 25.56% to Rs 82.33 crore in the quarter ended September 2024 as against Rs 65.57 crore during the previous quarter ended September 2023. Sales rose 2.78% to Rs 313.41 crore in the quarter ended September 2024 as against Rs 304.93 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales313.41304.93 3 OPM %36.3929.08 - PBDT117.1794.53 24 PBT111.4088.05 27 NP82.3365.57 26 Powered by Capital Market - Live

8 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Procter & Gamble Health Ltd (PGHL) today?

    The share price of PGHL as on 10th July 2025 is ₹5677.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Procter & Gamble Health Ltd (PGHL) share?

    The past returns of Procter & Gamble Health Ltd (PGHL) share are
    • Past 1 week: -2.84%
    • Past 1 month: -0.24%
    • Past 3 months: 8.74%
    • Past 6 months: 7.97%
    • Past 1 year: 9.67%
    • Past 3 years: 32.87%
    • Past 5 years: 36.53%

  3. What are the peers or stocks similar to Procter & Gamble Health Ltd (PGHL)?
  4. What is the dividend yield % of Procter & Gamble Health Ltd (PGHL) share?

    The current dividend yield of Procter & Gamble Health Ltd (PGHL) is 4.58.

  5. What is the market cap of Procter & Gamble Health Ltd (PGHL) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Procter & Gamble Health Ltd (PGHL) is ₹9424.30 Cr as of 10th July 2025.

  6. What is the 52 week high and low of Procter & Gamble Health Ltd (PGHL) share?

    The 52-week high of Procter & Gamble Health Ltd (PGHL) is ₹6175.50 and the 52-week low is ₹4863.

  7. What is the PE and PB ratio of Procter & Gamble Health Ltd (PGHL) stock?

    The P/E (price-to-earnings) ratio of Procter & Gamble Health Ltd (PGHL) is 46.89. The P/B (price-to-book) ratio is 17.51.

  8. Which sector does Procter & Gamble Health Ltd (PGHL) belong to?

    Procter & Gamble Health Ltd (PGHL) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Procter & Gamble Health Ltd (PGHL) shares?

    You can directly buy Procter & Gamble Health Ltd (PGHL) shares on Tickertape. Simply sign up, connect your demat account and place your order.